China Biologic Produ (CBPO) 116.27 $CBPO
China Blood Product Industry Report, 2016-2019
PR Newswire - Mon Jun 06, 11:30PM CDT
Recombinant blood products have developed for many years in foreign countries, but China's blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.
CBPO: 116.27 (-1.51)
China Biologic Announces Secondary Offering of Common Stock
PR Newswire - Thu Jun 02, 3:53PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading plasma-based biopharmaceutical company in China, today announced that Warburg Pincus Private Equity X, L.P. ("WP X" , Warburg Pincus X Partners, L.P. ("WPP X" and WP X Biologics LLC (together with WP X and WPP X, the "Selling Stockholders" agreed to sell 2,775,000 shares of the Company's common stock in an underwritten public offering. China Biologic will not sell any shares in the offering and it will not receive any proceeds from the sale of the shares by the Selling Stockholders. Closing of the offering is expected to occur on or about June 8, 2016, subject to customary closing conditions. The total number of shares of common stock outstanding will not change as a result of this offering.
CBPO: 116.27 (-1.51)
China Biologic Reports Financial Results for the First Quarter of 2016
PR Newswire - Wed May 04, 4:00PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the first quarter of 2016.
CBPO: 116.27 (-1.51)
China Biologic Products to Report First Quarter 2016 Financial Results
PR Newswire - Fri Apr 22, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2016 financial results on Wednesday, May 4, 2016 after the market closes.
CBPO: 116.27 (-1.51)
New Strong Sell Stocks for February 5th
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
CBPO: 116.27 (-1.51), ABB: 20.68 (-0.46), AHGP: 20.01 (+0.11), ACTG: 5.09 (+0.12), BANR: 42.97 (-0.88)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 116.27 (-1.51), VICL: 4.20 (-0.35), CMRX: 4.14 (-0.44), PFE: 35.29 (-0.02), MRK: 56.81 (-0.37), ATRA: 19.53 (-0.57), VBIV: 4.36 (+0.12), GSK: 40.93 (-1.13), NVS: 78.94 (-1.57)
Thrombosis Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s4vxk/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thrombosis Overview - Therapeutics Development - Pipeline Products for Thrombosis - Overview - Pipeline Products for Thrombosis - Comparative Analysis - Thrombosis - Therapeutics under Development by Companies - Thrombosis - Therapeutics under Investigation by Universities/Institutes - Thrombosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thrombosis - Products under Development by Companies - Thrombosis - Products under Investigation by Universities/Institutes - Thrombosis - Companies Involved in Therapeutics Development - 3SBio Inc. - Antibe Therapeutics, Inc. - Archemix Corp. - Arena Pharmaceuticals, Inc. - Armetheon, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - Cereno Scientific AB - China Biologic Products, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dyax Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - GlycoMimetics, Inc. - Green Cross Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - LG Life Science LTD. - Lipicard Technologies Limited - Merrion Pharmaceuticals Plc - Pfizer Inc. - PLx Pharma Inc. - Portola Pharmaceuticals, Inc. - Prothix BV - Sagene Pharmaceuticals, Inc. - Sanofi - SciFluor Life Sciences, LLC - The International Biotechnology Center (IBC) Generium - Zedira GmbH - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/5s4vxk/thrombosis
PTLA: 26.38 (-0.46), ARWR: 5.85 (-0.14), PFE: 35.29 (-0.02), GLYC: 8.50 (+0.13), BMY: 72.65 (-0.08), DYAX: 38.04 (-0.37), CBPO: 116.27 (-1.51), JNJ: 117.01 (+0.01), AZN: 27.97 (-0.99), PLXP: (), ARNA: 1.99 (-0.07)
China Biologic Products: CBPO Falls 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 8:20AM CST
China Biologic Products (CBPO) saw a big move last session, as the company's shares fell by over 5% on the day.
CBPO: 116.27 (-1.51), BXLT: 46.02 (-0.18)
China Biologic to Attend the 34th Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 04, 7:30AM CST
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company will participate in the 34th Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel, San Francisco, California, January 11-14, 2016.
CBPO: 116.27 (-1.51), JPM: 63.84 (-0.91)
15 Best Stocks to Ring Out the Old, Ring In the New
Sweta Killa - Zacks Investment Research - Thu Dec 31, 8:20AM CST
We have highlighted the best 15 stocks of 2015 sporting either a Zacks Rank #1 or #2 and backed with a solid industry Rank.
CBPO: 116.27 (-1.51), ATVI: 37.77 (-0.77), QUNR: 28.17 (-1.22), GLOB: 38.66 (-0.75), LXRX: 14.55 (+0.10), LGND: 113.74 (-1.34), EBIX: 47.35 (-1.55), EGRX: 53.00 (+11.53), DYAX: 38.04 (-0.37), AMWD: 65.28 (-0.43), SWHC: 21.41 (-0.60)
The Zacks Analyst Blog Highlights: Alibaba, China Biologic Products, Weibo, JinkoSolar Holding and Momo
Zacks Equity Research - Zacks Investment Research - Thu Dec 24, 8:30AM CST
The Zacks Analyst Blog Highlights: Alibaba, China Biologic Products, Weibo, JinkoSolar Holding and Momo
CBPO: 116.27 (-1.51), WB: 27.08 (-0.71), MOMO: 12.18 (-0.36), JKS: 20.00 (-1.30), BABA: 75.92 (-1.64)
Can the Rally in China Biologic Products (CBPO) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Thu Dec 24, 6:33AM CST
As of late, it has definitely been a great time to be an investor in China Biologic Products Inc (CBPO)
CBPO: 116.27 (-1.51)
Forget Alibaba, Bet on These 5 Winning China Stocks of 2015
Swarup Gupta - Zacks Investment Research - Wed Dec 23, 12:41PM CST
The Shanghai Composite has gained 12.4% year-to-date even as the S&P 500 languishes in the red.
CBPO: 116.27 (-1.51), SOL: 1.30 (-0.05), WB: 27.08 (-0.71), MOMO: 12.18 (-0.36), BABA: 75.92 (-1.64), JKS: 20.00 (-1.30)
China Biologic Products posts 3Q profit
Automated Insights - Tue Nov 03, 6:09PM CST
BEIJING (AP) _ China Biologic Products Inc. (CBPO) on Tuesday reported third-quarter profit of $22.9 million.
CBPO: 116.27 (-1.51)
Research and Markets: Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015 Featuring Biotest AG, China Biologic Products, Grifols, LFB S.A. & Octapharma AG
BusinessWire - Fri Oct 23, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gwhk3j/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015" report to their offering.
CBPO: 116.27 (-1.51)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015 Featuring Biotest AG, China Biologic Products, Grifols, LFB S.A. & Octapharma AG
M2 - Fri Oct 23, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qs4cs3/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Biotest AG - China Biologic Products, Inc. - Grifols, S.A. - LFB S.A. - Octapharma AG For more information visit http://www.researchandmarkets.com/research/qs4cs3/fibrinogen
CBPO: 116.27 (-1.51)
China Blood Product Industry Report, 2016-2019
PR Newswire - Mon Jun 06, 11:30PM CDT
Recombinant blood products have developed for many years in foreign countries, but China's blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.
CBPO: 116.27 (-1.51)
China Biologic Announces Secondary Offering of Common Stock
PR Newswire - Thu Jun 02, 3:53PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading plasma-based biopharmaceutical company in China, today announced that Warburg Pincus Private Equity X, L.P. ("WP X" , Warburg Pincus X Partners, L.P. ("WPP X" and WP X Biologics LLC (together with WP X and WPP X, the "Selling Stockholders" agreed to sell 2,775,000 shares of the Company's common stock in an underwritten public offering. China Biologic will not sell any shares in the offering and it will not receive any proceeds from the sale of the shares by the Selling Stockholders. Closing of the offering is expected to occur on or about June 8, 2016, subject to customary closing conditions. The total number of shares of common stock outstanding will not change as a result of this offering. CBPO: 116.27 (-1.51)
China Biologic Reports Financial Results for the First Quarter of 2016
PR Newswire - Wed May 04, 4:00PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the first quarter of 2016. CBPO: 116.27 (-1.51)
China Biologic Products to Report First Quarter 2016 Financial Results
PR Newswire - Fri Apr 22, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2016 financial results on Wednesday, May 4, 2016 after the market closes. CBPO: 116.27 (-1.51)
New Strong Sell Stocks for February 5th
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
CBPO: 116.27 (-1.51), ABB: 20.68 (-0.46), AHGP: 20.01 (+0.11), ACTG: 5.09 (+0.12), BANR: 42.97 (-0.88)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 116.27 (-1.51), VICL: 4.20 (-0.35), CMRX: 4.14 (-0.44), PFE: 35.29 (-0.02), MRK: 56.81 (-0.37), ATRA: 19.53 (-0.57), VBIV: 4.36 (+0.12), GSK: 40.93 (-1.13), NVS: 78.94 (-1.57)
Thrombosis Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s4vxk/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thrombosis Overview - Therapeutics Development - Pipeline Products for Thrombosis - Overview - Pipeline Products for Thrombosis - Comparative Analysis - Thrombosis - Therapeutics under Development by Companies - Thrombosis - Therapeutics under Investigation by Universities/Institutes - Thrombosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thrombosis - Products under Development by Companies - Thrombosis - Products under Investigation by Universities/Institutes - Thrombosis - Companies Involved in Therapeutics Development - 3SBio Inc. - Antibe Therapeutics, Inc. - Archemix Corp. - Arena Pharmaceuticals, Inc. - Armetheon, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - Cereno Scientific AB - China Biologic Products, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dyax Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - GlycoMimetics, Inc. - Green Cross Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - LG Life Science LTD. - Lipicard Technologies Limited - Merrion Pharmaceuticals Plc - Pfizer Inc. - PLx Pharma Inc. - Portola Pharmaceuticals, Inc. - Prothix BV - Sagene Pharmaceuticals, Inc. - Sanofi - SciFluor Life Sciences, LLC - The International Biotechnology Center (IBC) Generium - Zedira GmbH - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/5s4vxk/thrombosis
PTLA: 26.38 (-0.46), ARWR: 5.85 (-0.14), PFE: 35.29 (-0.02), GLYC: 8.50 (+0.13), BMY: 72.65 (-0.08), DYAX: 38.04 (-0.37), CBPO: 116.27 (-1.51), JNJ: 117.01 (+0.01), AZN: 27.97 (-0.99), PLXP: (), ARNA: 1.99 (-0.07)
China Biologic Products: CBPO Falls 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 8:20AM CST
China Biologic Products (CBPO) saw a big move last session, as the company's shares fell by over 5% on the day.
CBPO: 116.27 (-1.51), BXLT: 46.02 (-0.18)
China Biologic to Attend the 34th Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 04, 7:30AM CST
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company will participate in the 34th Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel, San Francisco, California, January 11-14, 2016. CBPO: 116.27 (-1.51), JPM: 63.84 (-0.91)
15 Best Stocks to Ring Out the Old, Ring In the New
Sweta Killa - Zacks Investment Research - Thu Dec 31, 8:20AM CST
We have highlighted the best 15 stocks of 2015 sporting either a Zacks Rank #1 or #2 and backed with a solid industry Rank.
CBPO: 116.27 (-1.51), ATVI: 37.77 (-0.77), QUNR: 28.17 (-1.22), GLOB: 38.66 (-0.75), LXRX: 14.55 (+0.10), LGND: 113.74 (-1.34), EBIX: 47.35 (-1.55), EGRX: 53.00 (+11.53), DYAX: 38.04 (-0.37), AMWD: 65.28 (-0.43), SWHC: 21.41 (-0.60)
The Zacks Analyst Blog Highlights: Alibaba, China Biologic Products, Weibo, JinkoSolar Holding and Momo
Zacks Equity Research - Zacks Investment Research - Thu Dec 24, 8:30AM CST
The Zacks Analyst Blog Highlights: Alibaba, China Biologic Products, Weibo, JinkoSolar Holding and Momo
CBPO: 116.27 (-1.51), WB: 27.08 (-0.71), MOMO: 12.18 (-0.36), JKS: 20.00 (-1.30), BABA: 75.92 (-1.64)
Can the Rally in China Biologic Products (CBPO) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Thu Dec 24, 6:33AM CST
As of late, it has definitely been a great time to be an investor in China Biologic Products Inc (CBPO)
CBPO: 116.27 (-1.51)
Forget Alibaba, Bet on These 5 Winning China Stocks of 2015
Swarup Gupta - Zacks Investment Research - Wed Dec 23, 12:41PM CST
The Shanghai Composite has gained 12.4% year-to-date even as the S&P 500 languishes in the red.
CBPO: 116.27 (-1.51), SOL: 1.30 (-0.05), WB: 27.08 (-0.71), MOMO: 12.18 (-0.36), BABA: 75.92 (-1.64), JKS: 20.00 (-1.30)
China Biologic Products posts 3Q profit
Automated Insights - Tue Nov 03, 6:09PM CST
BEIJING (AP) _ China Biologic Products Inc. (CBPO) on Tuesday reported third-quarter profit of $22.9 million.
CBPO: 116.27 (-1.51)
Research and Markets: Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015 Featuring Biotest AG, China Biologic Products, Grifols, LFB S.A. & Octapharma AG
BusinessWire - Fri Oct 23, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gwhk3j/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015" report to their offering.
CBPO: 116.27 (-1.51)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015 Featuring Biotest AG, China Biologic Products, Grifols, LFB S.A. & Octapharma AG
M2 - Fri Oct 23, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qs4cs3/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Biotest AG - China Biologic Products, Inc. - Grifols, S.A. - LFB S.A. - Octapharma AG For more information visit http://www.researchandmarkets.com/research/qs4cs3/fibrinogen
CBPO: 116.27 (-1.51)
